News & Updates
Filter by Specialty:
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022Molnupiravir and nirmatrelvir/ritonavir show favourable hepatic safety in COVID-19 patients in HK
A territory-wide cohort study in Hong Kong shows favourable hepatic safety profile with the oral antivirals, molnupiravir and nirmatrelvir/ritonavir, in COVID-19 patients, including those at risk of drug-induced liver injury (DILI).
Molnupiravir and nirmatrelvir/ritonavir show favourable hepatic safety in COVID-19 patients in HK
29 Sep 2022Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
28 Sep 2022First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.